ExSight Ventures appeared to be the VC, which was created in 2014. The main office of represented VC is situated in the New York. The venture was found in North America in United States.
The fund has exact preference in some founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Genetics, Biotechnology. Among the various public portfolio startups of the fund, we may underline ONL Therapeutics, RetroSense Therapeutics, lensgen Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Comparing to the other companies, this ExSight Ventures performs on 9 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2016. The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 5 participants. Despite the ExSight Ventures, startups are often financed by National Institutes of Health, MedTech Innovator, Tech Coast Angels. The meaningful sponsors for the fund in investment in the same round are InFocus Capital Partners, Hatteras Venture Partners, Aju IB Investment. In the next rounds fund is usually obtained by InFocus Capital Partners, HOYA Group, Invest Michigan.
We also calculated 5 valuable employees in our database.
Funds with similar focus
|A/O Proptech||England, London, United Kingdom|
|Alzheimer's Foundation of America||New York, New York, United States|
|Arali Ventures||Bangalore, India, Karnataka|
|Efficient Networks||Dallas, Texas, United States|
|Guangdong Bobaolon||China, Guangdong Province, Jieyang City|
|International Copper Association||-|
|Juroku Lease||Gifu, Gifu Prefecture, Japan|
|Lowenthal Capital Partners||California, Davis, United States|
|MLV & Co.||New York, New York, United States|
|Pingan Caizhi||China, Guangdong, Shenzhen|
|Red Dog Capital||California, Palo Alto, United States|
|Tfund||Connecticut, United States, Wallingford|
|Tracsis||England, Leeds, United Kingdom|
|$100M||01 Mar 2021||San Diego, California, United States|
|$46M||22 Dec 2020||Ann Arbor, Michigan, United States|
|$3M||02 Jun 2020||Northern Ireland|
|$10M||06 Jan 2020||San Diego, California, United States|
|$28M||16 Jul 2019||San Diego, California, United States|
|$4M||17 May 2017||Ann Arbor, Michigan, United States|
|$21M||01 May 2017||Irvine, California, United States|
|$5M||05 Jan 2017||San Diego, California, United States|
|$6M||12 Nov 2015||Ann Arbor, Michigan, United States|
– DTx Pharma, Inc. from San Diego raised $100m in Series B financing.
– The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures.
– The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.